Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A molecular scaffold bearing eight terminal alkyne groups was synthesized from sucrose. Eight copies of an azide-terminated, azo-linked precursor to 5-aminosalicylic acid were attached to the scaffold via copper(I)-catalyzed azide-alkyne cycloaddition. The resulting compound was evaluated in a DSS model of colitis in BALB/c mice against sulfasalazine as a control. Two independent studies verified that the novel pro-drug, administered in a dose calculated to result in an equimolar 5-ASA yield, outperformed sulfasalazine in terms of protection from mucosal inflammation and T cell activation. A separate study established that 5-ASA appeared in feces produced 24-48 hours following administration of the pro-drug. Thus, a new, orally administered pro-drug form of 5-aminosalicylic acid has been developed and successfully demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460528 | PMC |
| http://dx.doi.org/10.1021/ml300086c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Immune-related colitis after immune checkpoint inhibitor rechallenging: a case report].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Immune-related adverse events (irAE) are treatment-associated complications that single or multiple systems could be involved after immune checkpoint inhibitors(ICI), ranging from mild to life-threatening diseases, with significant heterogeneity. This is an important factor which might affect continuous ICI treatment. Patients who have experienced mild to moderate irAE could try ICI rechallenge after they recovered from irAE.
View Article and Find Full Text PDFUlcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy. Case 1 involved a 29-year-old man who developed continuous inflammation extending from the stomach to the jejunum 1 month after an initial UC diagnosis.
View Article and Find Full Text PDFIntroduction: Lower urinary tract symptoms are common in patients with inflammatory bowel disease; however, the association between ulcerative colitis and chronic prostatitis remains underrecognized.
Case Presentation: A 38-year-old man presented with frequent and painful urination unresponsive to the standard treatment of chronic prostatitis. He was subsequently diagnosed with ulcerative colitis based on persistent hematochezia and colonoscopy findings.
Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy.
World J Gastroenterol
August 2025
Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
Background: 5-aminosalicylates (5-ASA) are the primary treatment for mild to moderate ulcerative colitis (UC). Maintenance therapy with 5-ASA has been shown to reduce both the risk of relapse and colorectal cancer.
Aim: To evaluate the outcomes of 5-ASA withdrawal due to non-adherence in UC patients while in remission on monotherapy.
Risk of Kidney Impairment during Iguratimod Therapy for Rheumatoid Arthritis Patients: The Role of Concomitant Salazosulfapyridine.
Intern Med
September 2025
Department of Rheumatology, University of Yamanashi Hospital, Japan.
Background Iguratimod (IGU) is a synthetic disease-modifying anti-rheumatic drug that is mainly used in East Asia. Kidney impairment related to IGU may be under-recognized, and its proportion, severity, and risk factors remain unclear. Objectives To assess the influence of IGU on the kidney function among RA) and to clarify the risk factors associated with kidney impairment.
View Article and Find Full Text PDF